Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

Point-of-Sale Rebates Gaining Traction In Employer-Sponsored Insurance

Survey by National Business Group on Health also finds growing momentum behind use of copay accumulator programs.

Policy Private Payers

CVS Will Retain $300M In Drug Rebates In 2018, PBM Says

CEO Merlo downplays importance of rebates to the firm’s financials as he rebuts accusations that PBMs cause high list prices for drugs.

Pricing Debate Pharmacy Benefit Management

CVS Launching Program To Exclude New Drugs Deemed Not Cost Effective

Program would use cost per QALY determinations by the Institute for Clinical and Economic Review.
Pricing Debate Policy

Highest-Cost Drugs Could Feel Biggest Pinch From Part B Step Therapy Policy

Biosimilars for Remicade and Neulasta could get boost, and off-label Avastin use for age-related macular degeneration could increase, challenging Eylea and Lucentis.

Pricing Strategies Medicare

Step Therapy For Medicare Part B Drugs Will Lower Costs By 20%, HHS Projects

Beginning in 2019, Medicare Advantage plans may use step therapy in Part B, potentially including “cross management” with Part D drugs, under new guidance from the Centers for Medicare and Medicaid Services.

Pricing Debate Medicare

Express Scripts Rewards Low List-Priced Brands In 2019 Formulary, Retains Focus On Rebates

Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018.

Pharmacy Benefit Management Pricing Strategies
See All